Tarsus Pharmaceuticals (TARS) Insider Goldberg Buys 2,954 Shares

Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.

Andrew Goldberg bought 2,954 shares of Tarsus Pharmaceuticals, Inc. (TARS) on June 12, 2026. The shares were purchased at a price of $61.85 each, valuing the transaction at about $183,000. This purchase highlights Goldberg's continued interest in the company, which focuses on developing innovative therapies for eye care.

Previous Insider Transactions

This latest buy comes after Goldberg sold 2,954 shares of Tarsus on the same day. On June 25, 2026, he also acquired 3,837 shares, showing a pattern of active trading. Other insiders have been active as well; on June 15, 2026, Katherine Goodrich sold 2,954 shares for over $183,000. Similarly, on June 12, Scott Morrison and Wendy Yarno both sold 2,954 shares each.

Analysts Set New Price Targets

Analysts have a generally positive outlook on Tarsus Pharmaceuticals. On September 8, 2026, Jefferies maintained a "Buy" rating with a target price of $105, up from $88. Oppenheimer also kept its "Outperform" rating with a target of $100 on August 12, 2026. Mizuho maintained an "Outperform" rating with a target of $98 on July 31, 2026. This collective sentiment suggests confidence in the company's future performance.

How TARS Stock Has Traded

The stock is currently trading at $61.85, which is significantly below its 52-week high of $91.53. Tarsus has a market cap of about $3.62 billion and has shown considerable revenue growth of 69.4% recently. This backdrop of insider buying and favorable analyst ratings may provide a supportive environment for the stock moving forward.

What TARS Does

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company based in Irvine, California. It specializes in developing treatments for eye care, including its product XDEMVY, which treats demodex blepharitis. The company's focus on innovative therapies positions it well within the biotechnology sector.

What's Ahead for TARS

Tarsus Pharmaceuticals is set to announce its next earnings report on November 4, 2026. Investors will be watching closely for updates on its pipeline and further developments in the company's products. The recent insider activity, including Andrew Goldberg's purchase, may indicate a positive outlook for the company, although the 13F filings reflect past holdings and may not represent current positions.